Quoin Pharmaceuticals (QNRX) Research & Development (2021 - 2026)
Quoin Pharmaceuticals (QNRX) posted Research & Development of $3.4 million for Q1 2026, up 10.88% sequentially from $3.1 million in Q4 2025, and up 44.63% YoY from $2.4 million in Q1 2025.
Quoin Pharmaceuticals (QNRX) Research & Development (2021 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Research & Development for 6 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Research & Development rose 44.63% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 113.35% YoY) and the FY2025 annual result came in at $9.8 million, up 172.1% from the prior year.
- Research & Development climbed to $3.4 million in Q1 2026 per QNRX's latest filing, from $3.1 million in the prior quarter.
- Over five years, Research & Development peaked at $3.4 million in Q1 2026 and troughed at $587503.0 in Q2 2024.
- A 5-year average of $1.4 million and a median of $885298.0 in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development declined 18.91% in 2024, then soared 249.03% in 2025.
- Over 5 years, Research & Development stood at $830000.0 in 2022, then increased by 0.29% to $832391.0 in 2023, then increased by 26.17% to $1.1 million in 2024, then jumped by 194.88% to $3.1 million in 2025, then increased by 10.88% to $3.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.4 million, $3.1 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Quoin Pharmaceuticals | 491,038.58 | 491,038.58 | - | 3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.43 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 587,503.00 |
| Mar 31, 2024 | 885,298.00 |
| Dec 31, 2023 | 832,391.00 |
| Sep 30, 2023 | 758,759.00 |
| Jun 30, 2023 | 625,104.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 830,000.00 |
| Sep 30, 2022 | 745,506.00 |
| Jun 30, 2022 | 726,694.00 |
| Mar 31, 2022 | 587,569.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 259,996.00 |
| Jun 30, 2021 | 239,280.00 |